Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | MTOR | P42345 | 3/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | POLR1A | O95602 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202108 | 0.84 | L3MBTL3 (0.39) | PIK3CAMTOR | |
| SCHEMBL2199894 | 0.79 | HAO1 (0.36) | — | |
| SCHEMBL2203835 | 0.78 | PARP1 (0.36) | PIK3CAMTOR | |
| SCHEMBL2198709 | 0.77 | MAPT (0.36) | — | |
| SCHEMBL2198108 | 0.73 | KMT2A (0.41) | JAK1PIK3CAMTORKDM1APOLR1A | |
| SCHEMBL2199721 | 0.67 | MALT1 (0.37) | JAK1KDM1APOLR1A | |
| SCHEMBL2197614 | 0.67 | KMT2A (0.44) | JAK1KDM1APOLR1A | |
| SCHEMBL12510462 | 0.66 | KMT2A (0.43) | JAK1KDM1APOLR1A | |
| SCHEMBL2200002 | 0.64 | KMT2A (0.47) | JAK1KDM1APOLR1A | |
| SCHEMBL2202091 | 0.62 | MALT1 (0.40) | JAK1KDM1APOLR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | JAK1 553/4885PIK3CA 3765/4885MTOR 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.